Sharemaestro Newsreel

Cigna Group stock holds steady as a major U.S. health insurer with diversified benefits business

Cigna Group's stock reflects its standing as a major U.S. health insurer and benefits provider, offering a diversified portfolio that includes commercial and government health plans, pharmacy benefits, and international services. The company's strategy emphasizes diversification across these segments, combining traditional insurance with service-based …

Elevance Health (ELV) Q2 2025 earnings summary

Elevance Health reported Q2 2025 operating revenue of $49.4 billion, a 14.3% year-over-year increase, driven by higher premium yields and Medicare Advantage growth, but net income decreased by 24.2% to $1.74 billion due to elevated medical costs. The company revised its full-year 2025 adjusted …

Kaplan Fox Reminds Investors of an Ongoing Investigation Into Alignment Healthcare, Inc. (NASDAQ: ALHC) for Possible Securities Law Violations

Kaplan Fox & Kilsheimer LLP is investigating Alignment Healthcare, Inc. (NASDAQ: ALHC) for potential securities law violations following a whistleblower complaint. The complaint alleges "accounting irregularities" that "artificially inflated" the company's financial results by misclassifying operating expenses as capital expenditures. Following this news on …

Is Molina Healthcare Inc (MOH) a Bargain After 3.4% Drop? GF Value Says Undervalued

Molina Healthcare Inc (MOH) shares dropped 3.4% to $233.36, yet GuruFocus's GF Value suggests it is significantly undervalued by 42.4%, with a GF Value™ of $405.44. Despite a strong GF Score™ of 82/100, indicating good profitability and financial strength, the stock's current P/E ratio …

Sale of 12,712 shares planned in CLOV (Nasdaq: CLOV) notice

An affiliate of Clover Health Investments (Nasdaq: CLOV) plans to sell 12,712 Class A common shares, valued at $59,492.16, through Morgan Stanley Smith Barney LLC around July 15, 2026. These shares originated from restricted stock units granted as compensation. The filing also notes previous …

CLOV (Nasdaq: CLOV) plans Rule 144 sale of 60765 shares

Clover Health Investments, Corp. (Nasdaq: CLOV) has filed a Form 144 notice for the planned sale of 60,765 shares of Class A Common Stock. These shares originate from Restricted Stock Units granted as compensation and are scheduled to be sold on Nasdaq via Morgan …

CLOV (CLOV) plans sale of 23,463 Class A common shares

Clover Health Investments, Corp. (CLOV) has filed a Form 144 disclosing a planned sale of 23,463 shares of Class A Common Stock with an aggregate market value of $109,806.84 through Morgan Stanley Smith Barney LLC on July 15, 2026. These shares originated from restricted …

ALHC (NASDAQ: ALHC) insider plans sale of 177,068 common shares

A Form 144 filing indicates a proposed sale of 177,068 shares of Alignment Healthcare (ALHC) common stock with an aggregate market value of over $3.7 million. These shares originate from stock options exercised and RSU/PSU awards, and the sale will be facilitated by Morgan …

UnitedHealth Group stock holds steady as diversified health benefits and Optum growth shape the long-term story

UnitedHealth Group's stock reflects a diversified model combining health insurance and care delivery, driven by its Optum unit and broad US market exposure. The company offers a mix of defensive cash flows from its insurance segment and growth potential through Optum's health services. Its …

Appeals court tosses lawsuit accusing UnitedHealth of misleading seniors

A federal appeals court upheld a lower court's decision to dismiss a lawsuit against UnitedHealth Group, which accused the company of deceptively marketing its Medicare Advantage plans. The 9th U.S. Circuit Court of Appeals ruled that state laws cited by the plaintiffs, who alleged …

What CHROs need to know about health care affordability

CHROs and HR leaders convened at the SHRM Executive Network Experience 2026 to discuss the escalating and increasingly unpredictable costs of healthcare. Key takeaways included the impact of chronic conditions, accelerating medical innovation, and a fragmented healthcare system on affordability. The discussion emphasized the …

Will UnitedHealth (UNH) Beat Estimates Again in Its Next Earnings Report?

UnitedHealth Group (UNH) is poised to continue its streak of beating earnings estimates in its upcoming report, according to Zacks Equity Research. The company has a strong record of surpassing estimates, averaging 6.44% over the last two quarters, and currently holds a positive Zacks …

Elevance Health Inc. stock underperforms Wednesday when compared to competitors

Shares of Elevance Health Inc. (ELV) fell by 8.54% on Wednesday, closing at $390.33, despite a positive trading session for the broader stock market. The S&P 500 Index and the Dow Jones Industrial Average both saw gains, but Elevance Health's stock performance snapped a …

Scotiabank Adjusts Vistra Price Target to $298 From $293, Maintains Sector Outperform Rating

Scotiabank has increased its price target for Vistra Corp. from $293 to $298. The firm reiterated its "Sector Outperform" rating on Vistra, an integrated retail electricity and power generation company. This adjustment reflects Scotiabank's continued positive outlook on Vistra's performance within its sector.

MOH6320596 Bond Coupon Profile — Rate & Payments

This article provides the coupon profile for the Molina Healthcare, Inc. bond MOH6320596, detailing its interest rate and payment schedule. The bond has a current coupon rate of 6.50%, and the next payment is scheduled for August 17, 2026. It highlights the availability of …

Elevance Health (NYSE: ELV) logs $1,463M Q2 2026 shareholder profit

Elevance Health reported Q2 2026 revenues of $50,474 million, up slightly from the previous year, but shareholder net income declined to $1,463 million due to expenses growing faster than revenue. Diluted EPS for the quarter was $6.71, down from $7.72. The company also announced …

MOH6320596 Bond Risk Profile

This article provides a risk profile for the Molina Healthcare, Inc. 6.5% 15-FEB-2031 bond (MOH6320596). It highlights key metrics for assessing credit risk, including the bond's security level, inflation protection, and issuer rating. The platform offers access to analyst ratings and data from various …

Elevance Health, Inc. Q2 2026: Revenue $50.47B, EPS $6.71— 10-Q Summary

Elevance Health, Inc. reported its second-quarter 2026 results, showing total revenue of $50.47 billion, a modest increase year-over-year, while diluted EPS declined to $6.71. The company experienced an increase in operating revenue due to premium rate adjustments and growth in CarelonRx, despite a decrease …

Elevance Is Focused on Improving Margins While Facing Near-Term Challenges

Elevance Health, a major licensee of the Blue Cross Blue Shield brand in 14 states, is working to improve its margins despite immediate challenges. The company holds a strong market position, insuring about one-third of the population in its licensed states, which aids in …

Why Is Elevance Health Stock Sinking Wednesday? - Elevance Health (NYSE:ELV)

Elevance Health's stock is sinking despite beating Q2 earnings estimates and raising full-year guidance. Investors were reportedly underwhelmed as the guidance increase was smaller than the quarterly earnings beat, leading to a broader selloff among managed-care insurers. Elevated medical costs in government businesses also …

Agreement between Wexner Medical Center, Humana set to end in October

This article reports that the agreement between Wexner Medical Center and Humana is scheduled to terminate in October. No further details are provided regarding the implications or reasons for this termination.

Bought, Then Shuttered: What UnitedHealth Group did with the Behavioral Health Clinics it Acquired

UnitedHealth Group's Optum acquired hundreds of community mental-health practices and then closed more than half of them within three years, often with little warning to patients. This pattern affects access to critical in-person behavioral health services, including specialized care for eating disorders and autism. …

Elevance Health Releases Q2 2026 Financial Results

Elevance Health Inc. (ANTM) announced its Q2 2026 financial results, reporting adjusted diluted EPS of $7.45 and revenue of $49.83 billion, an increase of 0.8% year-over-year. The company's net income reached $1.62 billion, with medical membership totaling 44,949,000. For the next quarter, Elevance Health …

Earnings Flash (ELV) Elevance Health, Inc. Posts Q2 Adjusted EPS $7.45 per Share

Elevance Health, Inc. (ELV) reported an adjusted EPS of $7.45 per share for Q2 2026. The company also announced Q2 revenue of $49.83 billion, surpassing the FactSet estimated $48.84 billion, and raised its full-year adjusted EPS outlook. Following these results, several analysts adjusted their …

Elevance Health (NYSE:ELV) Reports Bullish Q2 CY2026

Elevance Health (NYSE:ELV) exceeded Wall Street's revenue and adjusted EPS expectations in Q2 CY2026, with sales up 2.1% year-on-year to $50.47 billion and non-GAAP profit of $7.45 per share. Despite a decrease in customer numbers, the company's operating margin significantly improved, and management slightly …

Elevance raises annual profit forecast on better medical cost management

Elevance Health has increased its annual profit forecast after exceeding second-quarter earnings expectations. This positive outlook is attributed to the company's effective medical cost management strategies. The insurer also reported a better-than-expected medical loss ratio, indicating efficient spending on medical care.

Humana (NYSE:HUM) Upgraded by Zacks Research to "Strong-Buy" Rating

Zacks Research has upgraded Humana (NYSE:HUM) to a "strong-buy" rating from "hold," despite the broader analyst consensus remaining at "Hold." This upgrade follows Humana's latest earnings report, which exceeded expectations with EPS of $10.31 and revenue of $39.65 billion, a 23.5% year-over-year increase. The …

Elevance Health Q2 Earnings Exceed Expectations

Elevance Health reported strong Q2 2026 earnings, surpassing expectations with a non-GAAP EPS of $7.45 and revenue of $49.83 billion. The company also upgraded its full-year 2026 diluted EPS and operating cash flow guidance, indicating a positive outlook. Analysts largely maintain optimistic ratings, with …

Elevance Health reports Q2 2026: Revenue $49.8B, Adj. diluted EPS $7.45, raises FY guidance

Elevance Health reported strong Q2 2026 results, with operating revenue reaching $49.8 billion and adjusted diluted EPS of $7.45. The company has raised its full-year 2026 guidance, projecting at least $20.10 diluted EPS and $27.00 adjusted diluted EPS, citing positive benefit expense performance and …

Elevance Health (NYSE: ELV) lifts 2026 EPS guidance on Q2 results

Elevance Health reported strong Q2 2026 results, exceeding expectations with operating revenue of $49.8 billion. The company raised its full-year 2026 diluted EPS guidance to at least $20.10 and adjusted diluted EPS guidance to at least $27.00, along with increasing operating cash flow guidance …

Elevance Raises Guidance on Lower-Than-Expected Medical Costs

Elevance Health Inc. has raised its annual profit guidance for the second consecutive quarter, signaling a positive trend for the health insurance industry amidst recent federal policy adjustments. The company now forecasts full-year adjusted earnings of at least $27 per share, an increase from …

Elevance Health beats estimates but shares fall on margin concerns

Elevance Health Inc. reported Q2 results that exceeded analyst expectations for adjusted EPS and revenue. However, shares fell more than 9% premarket due to concerns over declining operating margins, which dropped to 3.5% from 4.9% in the prior year quarter. Despite this, the company …

Elevance Health Reports $49.8B Revenue as Medical Costs Rise

Elevance Health reported Q2 2026 operating revenue of $49.8 billion, a 0.8% increase from the prior year, exceeding expectations. The company raised its full-year adjusted EPS guidance to at least $27.00, attributing it to strong operating results and strategic investments in medical cost management …

Compared to Estimates, Elevance Health (ELV) Q2 Earnings: A Look at Key Metrics

Elevance Health (ELV) reported Q2 2026 revenue of $49.83 billion and EPS of $7.45, exceeding Zacks Consensus Estimates by 2.85% and 20.55% respectively. The article highlights key financial metrics including medical membership across various segments and revenue breakdowns, demonstrating the company's strong performance relative …

Progyny (PGNY) Stock May Be 50% Undervalued On Fresh Analyst Upgrades

CVS Health (NYSE:CVS) Stock Rating Lowered by Wall Street Zen

Wall Street Zen has downgraded CVS Health (NYSE:CVS) from "buy" to "hold," despite other analysts raising price targets and a generally positive outlook from a broader analyst pool. CVS Health reported strong quarterly results, exceeding both earnings and revenue expectations, but faces ongoing regulatory …